Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study

OBJECTIVES: Results from the phase 3 Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) led to approval of nab-paclitaxel plus gemcitabine for first-line treatment of metastatic pancreatic cancer. The current analysis evaluated the effects of nab-paclitaxel plus gemcitabine versus gemcitabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunzmann, Volker, Ramanathan, Ramesh K., Goldstein, David, Liu, Helen, Ferrara, Stefano, Lu, Brian, Renschler, Markus F., Von Hoff, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266413/
https://www.ncbi.nlm.nih.gov/pubmed/27841795
http://dx.doi.org/10.1097/MPA.0000000000000742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266413/
https://www.ncbi.nlm.nih.gov/pubmed/27841795
http://dx.doi.org/10.1097/MPA.0000000000000742

Ejemplares similares